TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31784809

Group type: EXPERIMENTAL
Intervention: Single-Incision Mini-Sling (SIMS)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Transobturator Tape (TOT)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 105
Study: 29932230

Group type: EXPERIMENTAL
Intervention: 200‐mg selenium yeast tablets
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 145
Study: 28641972

Group type: EXPERIMENTAL
Intervention: Anterolateral surgical approach
Number of subjects: 49

Group type: COMPARATOR
Intervention: Posterior surgical approach
Number of subjects: 49
Study: 26169592

Group type: EXPERIMENTAL
Intervention: Patient decision aid (P-DA) with usual care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: P-DA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 0
Study: 23063567

Group type: EXPERIMENTAL
Intervention: Intravenous silibinin (SIL)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 20097683

Group type: EXPERIMENTAL
Intervention: Measurement of mid‐regional pro‐atrial natriuretic peptide (MR‐proANP)
Number of subjects: 1237

Group type: EXPERIMENTAL
Intervention: Measurement of mid‐regional pro‐adrenomedullin (MR‐proADM)
Number of subjects: 1237

Group type: EXPERIMENTAL
Intervention: Measurement of C‐terminal pro‐endothelin‐1 (CT‐proET‐1)
Number of subjects: 1237

Group type: EXPERIMENTAL
Intervention: Measurement of C‐terminal pro‐vasopressin (CT‐proAVP or copeptin)
Number of subjects: 1237
Study: 18375894

Group type: EXPERIMENTAL
Intervention: MA 20 mg
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: MA 40 mg
Number of subjects: 288

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 288
Study: 16725260

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 15055983

Group type: EXPERIMENTAL
Intervention: Crest Night Effects (19% sodium percarbonate)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Colgate Simply White Night (8.7% hydrogen peroxide)
Number of subjects: 57
Study: 10895743

Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine
Number of subjects: 802

Group type: COMPARATOR
Intervention: Intramuscular pethidine (up to 300 mg)
Number of subjects: 802
Study: 9073055

Group type: EXPERIMENTAL
Intervention: Radical surgery with pelvic lymphadenectomy (Group A, 72 patients)
Number of subjects: 92

Group type: COMPARATOR
Intervention: High-voltage external irradiation 40 Gy to a pelvic field (Group B, 70 patients)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Postoperative irradiation 40 to 50 Gy (Group A, if lymph node metastases found)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Surgery (Group A)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Radiotherapy (Group B)
Number of subjects: 92
Study: 1468089

Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg once daily
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg once daily
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg
Number of subjects: 544

Group type: COMPARATOR
Intervention: Lovastatin 40 mg
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Subset of patients
Number of subjects: 544
Study: 6242074

Group type: EXPERIMENTAL
Intervention: Topical clindamycin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oral tetracycline
Number of subjects: 20
Study: 31309775

Group type: EXPERIMENTAL
Intervention: IV ILO once monthly
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: IV ILO for 5 consecutive days every 3 months
Number of subjects: 96

Group type: COMPARATOR
Intervention: Not requiring therapy with IV ILO
Number of subjects: 96
Study: 30249366

Group type: EXPERIMENTAL
Intervention: Gemigliptin 50 mg once a day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg BID
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gemigliptin + Metformin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemigliptin
Number of subjects: 0
Study: 27658839

Group type: EXPERIMENTAL
Intervention: Inpatient psychotherapy (including EMDR)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Outpatient clinical management (control group)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Inpatient psychotherapy
Number of subjects: 38
Study: 25234012

Group type: EXPERIMENTAL
Intervention: Part-time patching for 3 hours daily for 5 months
Number of subjects: 358

Group type: COMPARATOR
Intervention: Observation (no treatment for 6 months)
Number of subjects: 358
Study: 22914450

Group type: EXPERIMENTAL
Intervention: Whole-body cooling to 33.5 °C for 72 hours
Number of subjects: 208

Group type: COMPARATOR
Intervention: Outborn infants (n = 93)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Inborn infants (n = 115)
Number of subjects: 208
Study: 20230254

Group type: EXPERIMENTAL
Intervention: Antofloxacin hydrochloride 200 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Antofloxacin hydrochloride 300 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Antofloxacin hydrochloride 400 mg
Number of subjects: 12
Study: 17266089

Group type: EXPERIMENTAL
Intervention: Early intervention (EI) with intraarticular methylprednisolone injections
Number of subjects: 59

Group type: COMPARATOR
Intervention: Conservative treatment (CT) with nonsteroidal antiinflammatory drugs
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Early intervention (EI) with sulfasalazine
Number of subjects: 59

Group type: COMPARATOR
Intervention: Conservative treatment (CT) with sulfasalazine
Number of subjects: 59
Study: 16186417

Group type: EXPERIMENTAL
Intervention: Postconditioning
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study: 11863285

Group type: EXPERIMENTAL
Intervention: Thalidomide extraction method using solid-phase extraction and liquid chromatography-tandem mass spectrometry
Number of subjects: 0
Study: 10522120

Group type: EXPERIMENTAL
Intervention: Computerised templates for asthma and diabetes management
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Qualitative assessment through semi-structured interviews
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Quantitative assessment through change in use of the template
Number of subjects: 6
Study: 7717632

Group type: EXPERIMENTAL
Intervention: Cochlear implant
Number of subjects: 0
Study: 1851183

Group type: EXPERIMENTAL
Intervention: hCRH (0.5 micrograms/kg)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: hCRH (1 microgram/kg)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: hCRH (2 micrograms/kg)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 5
Study: 7010014

Group type: EXPERIMENTAL
Intervention: Family care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Child-only care
Number of subjects: 0
Study: 31518174

Group type: EXPERIMENTAL
Intervention: TAM + OFS (5 years of Tamoxifen with 2 years of ovarian function suppression using monthly goserelin administration)
Number of subjects: 1483

Group type: COMPARATOR
Intervention: TAM-Only (5 years of Tamoxifen)
Number of subjects: 1483
Study: 31596369

Group type: EXPERIMENTAL
Intervention: Filtek Bulk Fill Posterior Restorative (FBF)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Charisma Smart Composite (CSC)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Equia Forte Fil (EF)
Number of subjects: 54
Study: 28698350

Group type: EXPERIMENTAL
Intervention: nanocurcumin (40 mg capsules, 2 per day for 3 months)
Number of subjects: 84

Group type: COMPARATOR
Intervention: placebo (40 mg capsules, 2 per day for 3 months)
Number of subjects: 84
Study: 26191648

Group type: EXPERIMENTAL
Intervention: AMA-SGD
Number of subjects: 3

Group type: COMPARATOR
Intervention: AMA-N
Number of subjects: 3

Group type: COMPARATOR
Intervention: Y-SGD
Number of subjects: 3
Study: 23381521

Group type: EXPERIMENTAL
Intervention: Enhanced support for shared decision making
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual level of support
Number of subjects: 0
Study: 22616228

Group type: EXPERIMENTAL
Intervention: Hypoxic preconditioning (HP) during CABG, one cycle of 10-minute hypoxemia followed by a 5-minute reoxygenation.
Number of subjects: 47

Group type: COMPARATOR
Intervention: No renal protection (comparison group).
Number of subjects: 47
Study: 20368202

Group type: EXPERIMENTAL
Intervention: Glyburide plus muraglitazar 2.5 mg
Number of subjects: 583

Group type: EXPERIMENTAL
Intervention: Glyburide plus muraglitazar 5 mg
Number of subjects: 583

Group type: EXPERIMENTAL
Intervention: Glyburide plus muraglitazar (both doses)
Number of subjects: 583

Group type: COMPARATOR
Intervention: Glyburide plus placebo
Number of subjects: 583
Study: 17473298

Group type: EXPERIMENTAL
Intervention: Intravenous levosimendan
Number of subjects: 1327

Group type: COMPARATOR
Intervention: Intravenous dobutamine
Number of subjects: 1327
Study: 15367726

Group type: EXPERIMENTAL
Intervention: Carbamazepine (800 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (1200 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Levetiracetam (1500 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 11740041

Group type: EXPERIMENTAL
Intervention: Health message focusing on smokers' sensory perceptions of Light and Ultra Light cigarettes
Number of subjects: 2120

Group type: COMPARATOR
Intervention: Health message focusing on vent holes
Number of subjects: 2120

Group type: COMPARATOR
Intervention: Health message focusing on health consequences of smoking
Number of subjects: 2120
Study: 11541259

Group type: EXPERIMENTAL
Intervention: Hypoxic-optokinetic stimulus (HOS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Optokinetic stimulus (OS)
Number of subjects: 20
Study: 8177898

Group type: EXPERIMENTAL
Intervention: Support offered by a nurse practitioner
Number of subjects: 0
Study: 2439977

Group type: EXPERIMENTAL
Intervention: Multidisciplinary infant development program (IDP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional care (control group)
Number of subjects: 0
Study: 29351799

Group type: EXPERIMENTAL
Intervention: MedDiet plus extravirgin OO, 20-30 g/day
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control MedDiet
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: MedDiet plus extravirgin OO
Number of subjects: 180
Study: 25946163

Group type: EXPERIMENTAL
Intervention: Strength and Conditioning (S&C) group (n = 8)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Endurance-Only (EO) group (n = 8)
Number of subjects: 16
Study: 25605469

Group type: EXPERIMENTAL
Intervention: PiCCO-derived physiological values
Number of subjects: 350

Group type: COMPARATOR
Intervention: Control group (CVP monitoring)
Number of subjects: 350
Study: 23658161

Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20060517

Group type: EXPERIMENTAL
Intervention: Metacognitive Therapy (MCT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Applied Relaxation (AR)
Number of subjects: 20
Study: 17851756

Group type: EXPERIMENTAL
Intervention: Decongestive therapy
Number of subjects: 408

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 408
Study: 16739389

Group type: EXPERIMENTAL
Intervention: Pacing modes that maintain atrioventricular synchrony
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization with specialized left ventricular leads
Number of subjects: 0
Study: 14622084

Group type: EXPERIMENTAL
Intervention: sibutramine
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Informing participants about realistic weight loss expectations (5% to 15%)
Number of subjects: 53
Study: 11157559

Group type: EXPERIMENTAL
Intervention: Standing with eyes open, feet together
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Standing with eyes closed, feet together
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Standing with eyes closed
Number of subjects: 6

Group type: COMPARATOR
Intervention: Standing with eyes open or closed, feet together or apart
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Standing with eyes closed or feet together
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Standing
Number of subjects: 6
Study: 9469128

Group type: EXPERIMENTAL
Intervention: Snoezelen in the snoezelen room
Number of subjects: 17

Group type: COMPARATOR
Intervention: Living room (control)
Number of subjects: 17
Study: 7938858

Group type: EXPERIMENTAL
Intervention: Caudal puncture and anesthesia with 2.5 mg/kg bupivacaine 1:200,000
Number of subjects: 140

Group type: COMPARATOR
Intervention: Lumbar puncture at L4‐L5 and 1.25 mg/kg of bupivacaine
Number of subjects: 140

Group type: COMPARATOR
Intervention: Epidural catheter in the caudal space up to L4‐L5 and 1.25 mg/kg of bupivacaine administered through the catheter
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Epidural catheter in the caudal space up to L4‐L5
Number of subjects: 140

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 140

Group type: COMPARATOR
Intervention: Groups 1 and 2
Number of subjects: 140

Group type: COMPARATOR
Intervention: Group 3
Number of subjects: 140
Study: 2836324

Group type: EXPERIMENTAL
Intervention: Imuthiol (Na diethyldithiocarbamate) adjuvant therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (patients vaccinated annually for several years)
Number of subjects: 0
Study: 30998526

Group type: EXPERIMENTAL
Intervention: Facebook
Number of subjects: 0

Group type: COMPARATOR
Intervention: Leaflets
Number of subjects: 0
Study: 28664763

Group type: EXPERIMENTAL
Intervention: Brief compassion focused imagery (CFI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Relaxation imagery (RI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both CFI and RI
Number of subjects: 0
Study: 28353023

Group type: EXPERIMENTAL
Intervention: GUM Hydral mouthwash plus gel
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Biotene Oralbalance mouthwash plus gel
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 40
Study: 26153784

Group type: EXPERIMENTAL
Intervention: scGOS/lcFOS/pAOS
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113

Group type: COMPARATOR
Intervention: Term control group
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: scGOS/lcFOS/pAOS and Placebo
Number of subjects: 113
Study: 23550740

Group type: EXPERIMENTAL
Intervention: Meloxicam TMOS
Number of subjects: 280

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 280
Study: 21467028

Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg
Number of subjects: 302

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study: 17963805

Group type: EXPERIMENTAL
Intervention: SSG+Alum/ALM+BCG
Number of subjects: 30

Group type: COMPARATOR
Intervention: SSG alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 16536204

Group type: EXPERIMENTAL
Intervention: Contamination of the adhesive surface with fresh saliva before light curing (A) - A1 subgroup: Saliva removed by gentle air blast; A2 subgroup: Saliva rinsed for 10 seconds, air-dried; A3 subgroup: Saliva rinsed, dried, adhesive re-applied.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Contamination of the adhesive surface with fresh saliva after light curing (B) - B1 subgroup: Saliva removed with gentle air blast; B2 subgroup: Saliva rinsed and dried; B3 subgroup: Saliva rinsed, dried, adhesive re-applied.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no contamination)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Xeno III - A1 subgroup
Number of subjects: 0
Study: 12752890

Group type: EXPERIMENTAL
Intervention: Intravenous conjugated equine oestrogen (25 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 20
Study: 11082823

Group type: EXPERIMENTAL
Intervention: Active transdermal nicotine patch
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 30
Study: 9337508

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Psychodynamic-interpersonal therapy
Number of subjects: 112
Study: 8402805

Group type: EXPERIMENTAL
Intervention: Chlorhexidine (0.12%, Peridex)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zinc and triclosan (high humectant)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control mouthwash
Number of subjects: 0
Study: 30968140

Group type: EXPERIMENTAL
Intervention: Very-low-carbohydrate high-fat breakfast (LCBF; <10% of energy from carbohydrate, 85% of energy from fat, 15% of energy from protein)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Dietary guidelines‐recommended nutrient profile breakfast (GLBF; 55% of energy from carbohydrate, 30% of energy from fat, 15% of energy from protein)
Number of subjects: 23
Study: 29178730

Group type: EXPERIMENTAL
Intervention: Toothpaste containing 5% potassium nitrate and 2% sodium fluoride
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Toothpaste containing 10% strontium chloride
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group treated with 22% carbamide peroxide followed by a toothpaste without active ingredient
Number of subjects: 60
Study: 25616881

Group type: EXPERIMENTAL
Intervention: Promethazine 6.25 mg IV
Number of subjects: 120

Group type: COMPARATOR
Intervention: Promethazine 12.5 mg IV
Number of subjects: 120
Study: 23255569

Group type: EXPERIMENTAL
Intervention: Low glycemic load diet (LGD)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Low-fat diet (LFD)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Both LGD and LFD
Number of subjects: 113
Study: 20940182

Group type: EXPERIMENTAL
Intervention: Abdominal massage
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (bowel management advice only)
Number of subjects: 30
Study: 18279487

Group type: EXPERIMENTAL
Intervention: Aminophylline 3 mg x kg(‐1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 16006428

Group type: EXPERIMENTAL
Intervention: Fish oil (4.5 g/d)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Olive oil (control)
Number of subjects: 100
Study: 12598354

Group type: EXPERIMENTAL
Intervention: EGF vaccine with montanide ISA 51 as adjuvant
Number of subjects: 40

Group type: COMPARATOR
Intervention: EGF vaccine with aluminum hydroxide as adjuvant
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide prevaccination treatment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: EGF vaccine (five doses)
Number of subjects: 40
Study: 9890172

Group type: EXPERIMENTAL
Intervention: Vinorelbine treatment (intravenous on days 1 and 8 of a 21-day cycle for six cycles)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Vinorelbine treatment
Number of subjects: 161

Group type: COMPARATOR
Intervention: Supportive care alone (Control)
Number of subjects: 161
Study: 15374185

Group type: EXPERIMENTAL
Intervention: Dihydroergokryptine (DEK) 5 mg bid for 2 weeks, 10 mg bid for 2 weeks, 20 mg bid for 11 months
Number of subjects: 215

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study: 1856491

Group type: EXPERIMENTAL
Intervention: Amphotericin B lipid complex (ABLC) at doses of 0.1, 0.25 mg/kg; 0.5 mg/kg not given to AB group.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Amphotericin B desoxycholate (AB) at doses of 0.1, 0.25 mg/kg.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Amphotericin B lipid complex (ABLC)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Amphotericin B desoxycholate (AB)
Number of subjects: 16
Study: 6348630

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.75% with epinephrine and/or hyaluronidase
Number of subjects: 111

Group type: COMPARATOR
Intervention: Lidocaine 2% with epinephrine and hyaluronidase
Number of subjects: 111
Study: 30987662

Group type: EXPERIMENTAL
Intervention: Chuna manual therapy (CMT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combined treatment (CMT + UC)
Number of subjects: 60
Study: 29548298

Group type: EXPERIMENTAL
Intervention: HRV biofeedback during exposure
Number of subjects: 80

Group type: COMPARATOR
Intervention: Motor pseudo-biofeedback task during exposure
Number of subjects: 80

Group type: COMPARATOR
Intervention: Two pseudo-biofeedback tasks during exposure
Number of subjects: 80

Group type: COMPARATOR
Intervention: No additional task during exposure
Number of subjects: 80
Study: 26801468

Group type: EXPERIMENTAL
Intervention: Use of iPad Airs for administering the Whooley questions and the Edinburgh Postnatal Depression Scale (EPDS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Survey layout with all questions on one screen and vertical scrolling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Survey layout with a single question per screen and multiple pages
Number of subjects: 0
Study: 24365987

Group type: EXPERIMENTAL
Intervention: Intravenous omeprazole at a dose of 0.5 mg/kg twice daily
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intravenous omeprazole at a dose of 1 mg/kg twice daily
Number of subjects: 40
Study: 22453270

Group type: EXPERIMENTAL
Intervention: Intensive 6-month weight loss program
Number of subjects: 338

Group type: COMPARATOR
Intervention: Educational program (control)
Number of subjects: 338
Study: 19464207

Group type: EXPERIMENTAL
Intervention: Cyanoacrylate
Number of subjects: 16

Group type: COMPARATOR
Intervention: Suturing
Number of subjects: 16
Study: 17325558

Group type: COMPARATOR
Intervention: Control group (n = 76)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: PG4 group (control formula supplemented with 4 g/L of a prebiotic blend, n = 74)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: PGL8 group (control formula supplemented with 8 g/L of a prebiotic blend, n = 76)
Number of subjects: 226
Study: 14723561

Group type: EXPERIMENTAL
Intervention: Cetuximab 400 mg/m2 initial dose followed by 250 mg/m2 weekly plus irinotecan (various doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cetuximab combined with irinotecan, fluorouracil and folinic acid (various regimens)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cetuximab monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cetuximab plus irinotecan
Number of subjects: 0
Study: 11728945

Group type: EXPERIMENTAL
Intervention: Selective COX‐2 inhibitors
Number of subjects: 0
Study: 9509201

Group type: COMPARATOR
Intervention: Isoflurane (IG)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Propofol (PG)
Number of subjects: 20